Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting.

Finkelstein J, Wood J, Crew KD, Kukafka R.

AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:58-67. eCollection 2017.


Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.

Yanes T, Meiser B, Young MA, Kaur R, Mitchell G, Barlow-Stewart K, Roscioli T, Halliday J, James P.

BMC Cancer. 2017 Jul 18;17(1):491. doi: 10.1186/s12885-017-3485-0.


How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS.

NPJ Breast Cancer. 2017 May 19;3:20. doi: 10.1038/s41523-017-0021-y. eCollection 2017.


Prognostic and predictive value of low estrogen receptor expression in breast cancer.

Bouchard-Fortier A, Provencher L, Blanchette C, Diorio C.

Curr Oncol. 2017 Apr;24(2):e106-e114. doi: 10.3747/co.24.3238. Epub 2017 Apr 27.


Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.

Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M.

Breast Cancer (Auckl). 2017 Mar 2;11:1178223417694520. doi: 10.1177/1178223417694520. eCollection 2017.


A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system.

Knerr S, Wernli KJ, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC.

Contemp Clin Trials. 2017 May;56:25-33. doi: 10.1016/j.cct.2017.02.009. Epub 2017 Feb 28.


Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study.

Kumar K, Peters S, Barton A; MATURA.

BMC Musculoskelet Disord. 2016 Nov 8;17(1):460.


Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.

Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, Finkelstein J, Infante K, Trivedi M, David R, Vargas J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2015 Nov 5;2015:1352-60. eCollection 2015.


A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.

Jupe ER, Dalessandri KM, Mulvihill JJ, Miike R, Knowlton NS, Pugh TW, Zhao LP, DeFreese DC, Manjeshwar S, Gramling BA, Wiencke JK, Benz CC.

BBA Clin. 2014 Nov 8;2:94-102. doi: 10.1016/j.bbacli.2014.11.001. eCollection 2014 Dec.


Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.

DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J.

Ecancermedicalscience. 2015 Nov 24;9:595. doi: 10.3332/ecancer.2015.595. eCollection 2015. Review.


Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.

Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN.

Front Oncol. 2015 Sep 29;5:208. doi: 10.3389/fonc.2015.00208. eCollection 2015. Erratum in: Front Oncol. 2015;5:271.


Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention.

Manni A, El-Bayoumy K, Skibinski CG, Thompson HJ, Santucci-Pereira J, Bidinotto LT, Russo J.

Biomed Res Int. 2015;2015:638645. doi: 10.1155/2015/638645. Epub 2015 Aug 3. Review.


Estrogens and Male Lower Urinary Tract Dysfunction.

Wynder JL, Nicholson TM, DeFranco DB, Ricke WA.

Curr Urol Rep. 2015 Sep;16(9):61. doi: 10.1007/s11934-015-0534-6. Review.


Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD.

Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.


Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.

Aktas B, Sorkin M, Pusztai L, Hofstatter EW.

Eur J Cancer Prev. 2016 Jan;25(1):3-8. doi: 10.1097/CEJ.0000000000000124.


Computational study of estrogen receptor-alpha antagonist with three-dimensional quantitative structure-activity relationship, support vector regression, and linear regression methods.

Chang YH, Chen JY, Hor CY, Chuang YC, Yang CB, Yang CN.

Int J Med Chem. 2013;2013:743139. doi: 10.1155/2013/743139. Epub 2013 May 14.


Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, Clemons M.

PLoS One. 2014 Oct 17;9(10):e110469. doi: 10.1371/journal.pone.0110469. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e116267.


The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.

Gingery A, Subramaniam M, Pitel KS, Reese JM, Cicek M, Lindenmaier LB, Ingle JN, Goetz MP, Turner RT, Iwaniec UT, Spelsberg TC, Hawse JR.

PLoS One. 2014 May 22;9(5):e98219. doi: 10.1371/journal.pone.0098219. eCollection 2014.


Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H.

J Clin Oncol. 2014 May 10;32(14):1427-36. doi: 10.1200/JCO.2013.51.2483. Epub 2014 Apr 7.


In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.

Hoskins LM, Werner-Lin A, Greene MH.

PLoS One. 2014 Feb 28;9(2):e87696. doi: 10.1371/journal.pone.0087696. eCollection 2014.

Supplemental Content

Support Center